La société biopharmaceutique a présenté des recherches sur la plateforme Hybrozyme lors de conférences internationales en mai et juin
Le bénéfice d'exploitation d'Alteogen au T2 atteint 34,2 milliards de wons, renoue avec les bénéfices
Reliability 66 · highLIVE9 min ago
- Right1
- Agency1
2 sources2 independent voices
no rewrites detected — all voices distinct
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
C'est ce qu'il a dit.
according to Yonhap News Agency
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Right1
Agency1
